Progesterone prevents development of neuropathic pain in a rat model: Timing and duration of treatment are critical

Journal of Pain Research

Volumn 4, Issue , 2011, Pages 91-101

  Dableh, Liliane J ^a   Henry, James L ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Neuropathic pain; Neuroprotection; Neurosteroid; Peripheral neuropathy; Progesterone; Recovery

Indexed keywords

EID: 80052470110     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S17009     Document Type: Article

References (64)

1. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: Risk factors and prevention. Lancet. 2006;367(9522):1618-1625.
2. Bordet T, Pruss RM. Targeting neuroprotection as an alternative approach to preventing and treating neuropathic pain. Neurotherapeutics. 2009;6(4):648-662.
3. Gilron I, Watson CP, Cahill CM, Moulin DE. Neuropathic pain: A practical guide for the clinician. CMAJ. 2006;175(3):265-275.
4. Boureau F, Doubrere JF, Luu M. Study of verbal description in neuropathic pain. Pain. 1990;42(2):145-152.
5. McDermott A, Toelle T, Rowbotham D, Schaefer C, Dukes E. The burden of neuropathic pain: Results from a cross-sectional survey. Eur J Pain. 2006;10(2):127-135.
6. Berger A. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain. 2004;5(3):143-149.
7. Attella MJ, Nattinville A, Stein DG. Hormonal state affects recovery from frontal cortex lesions in adult female rats. Behav Neural Biol. 1987;48(3):352-367.
8. Roof RL, Duvdevani R, Stein DG. Gender influences outcome of brain injury: Progesterone plays a protective role. Brain Res. 1993;607(1-2): 333-336.
9. Roof RL, Duvdevani R, Heyburn JW, Stein DG. Progesterone rapidly decreases brain edema: Treatment delayed up to 24 hours is still effective. Exp Neurol. 1996;138(2):246-251.
10. Roof RL, Duvdevani R, Braswell L, Stein DG. Progesterone facilitates cognitive recovery and reduces secondary neuronal loss caused by cortical contusion injury in male rats. Exp Neurol. 1994;129(1): 64-69.
11. Jiang N, Chopp M, Stein D, Feit H. Progesterone is neuroprotective after transient middle cerebral artery occlusion in male rats. Brain Res. 1996;735(1):101-107.
12. Jiang C, Wang J, Li X, Liu C, Chen N, Hao Y. Progesterone exerts neuroprotective effects by inhibiting inflammatory response after stroke. Inflamm Res. 2009;58(9):619-624.
13. Kumon Y, Kim SC, Tompkins P, Stevens A, Sakaki S, Loftus CM. Neuroprotective effect of postischemic administration of progesterone in spontaneously hypertensive rats with focal cerebral ischemia. J Neurosurg. 2000;92(5):848-852.
14. Cai W, Zhu Y, Furuya K, Li Z, Sokabe M, Chen L. Two different molecular mechanisms underlying progesterone neuroprotection against ischemic brain damage. Neuropharmacology. 2008;55(2): 127-138.
15. Ishrat T, Sayeed I, Atif F, Stein DG. Effects of progesterone administration on infarct volume and functional deficits following permanent focal cerebral ischemia in rats. Brain Res. 2009;1257:94-101.
16. Wang J, Jiang C, Liu C, Li X, Chen N, Hao Y. Neuroprotective effects of progesterone following stroke in aged rats. Behav Brain Res. 2010; 209(1):119-122.
17. Ogata T, Nakamura Y, Tsuji K, Shibata T, Kataoka K. Steroid hormones protect spinal cord neurons from glutamate toxicity. Neuroscience. 1993;55(2):445-449.
18. Labombarda F, Gonzalez SL, Gonzalez DM, Guennoun R, Schumacher M, de Nicola AF. Cellular basis for progesterone neuroprotection in the injured spinal cord. J Neurotrauma. 2002;19(3):343-355.
19. Gonzalez Deniselle MC, Lopez-Costa JJ, Saavedra JP, et al. Progesterone neuroprotection in the Wobbler mouse, a genetic model of spinal cord motor neuron disease. Neurobiol Dis. 2002;11(3):457-468.
20. El-Etr M, Vukusic S, Gignoux L, et al. Steroid hormones in multiple sclerosis. J Neurol Sci. 2005;233(1-2):49-54.
21. Stein DG, Wright DW, Kellermann AL. Does progesterone have neuroprotective properties? Ann Emerg Med. 2008;51(2):164-172.
22. Schumacher M, Guennoun R, Stein DG, De Nicola AF. Progesterone: Therapeutic opportunities for neuroprotection and myelin repair. Pharmacol Ther. 2007;116(1):77-106.
23. Wright DW, Kellermann AL, Hertzberg VS, et al. ProTECT: A randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med. 2007;49(4):391-402.
24. Xiao G, Wei J, Yan W, Wang W, Lu Z. Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: A randomized controlled trial. Crit Care. 2008;12(2):R61.
25. Stein DG, Wright DW. Progesterone in the clinical treatment of acute traumatic brain injury. Expert Opin Investig Drugs. 2010;19(17):847-857.
26. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. New Engl J Med 1998;339(5): 285-291.
27. Vukusic S, Hutchinson M, Hours M, et al. Pregnancy and multiple sclerosis (the PRIMS study): Clinical predictors of post-partum relapse. Brain. 2004;127(Pt 6):1353-1360.
28. Mosconi T, Kruger L. Fixed-diameter polyethylene cuffs applied to the rat sciatic nerve induce a painful neuropathy: Ultrastructural morphometric analysis of axonal alterations. Pain. 1996;64(1):37-57.
29. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994;53(1):55-63.
30. Pitcher GM, Ritchie J, Henry JL. Paw withdrawal threshold in the von Frey hair test is influenced by the surface on which the rat stands. J Neurosci Methods. 1999;87(2):185-193.
31. Gonzalez Deniselle MC, Lopez-Costa JJ, Saavedra JP, et al. Progesterone neuroprotection in the Wobbler mouse, a genetic model of spinal cord motor neuron disease. Neurobiol Dis. 2002;11(3): 457-468.
32. Roglio I, Bianchi R, Gotti S, et al. Neuroprotective effects of dihydroprogesterone and progesterone in an experimental model of nerve crush injury. Neuroscience. 2008;155(3):673-685.
33. Merskey H, Bogduk N. Classification of Chronic Pain. Volume 2. Seattle, WA: IASP Press; 1994.
34. Schumacher M, Guennoun R, Robert F, et al. Local synthesis and dual actions of progesterone in the nervous system: Neuroprotection and myelination. Growth Horm IGF Res. 2004;14 Suppl A:S18-S33.
35. Patte-Mensah C, Kibaly C, Boudard D, et al. Neurogenic pain and steroid synthesis in the spinal cord. J Mol Neurosci. 2006;28(1): 17-31.
36. Mensah-Nyagan AG, Do-Rego JL, Beaujean D, Luu-The V, Pelletier G, Vaudry H. Neurosteroids: Expression of steroidogenic enzymes and regulation of steroid biosynthesis in the central nervous system. Pharmacol Rev. 1999;51(1):63-81.
37. Su TP, London ED, Jaffe JH. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science. 1988;240(4849):219-221.
38. Valera S, Ballivet M, Bertrand D. Progesterone modulates a neuronal nicotinic acetylcholine receptor. Proc Natl Acad Sci U S A. 1992;89(20): 9949-9953.
39. Zhu Y, Bond J, Thomas P. Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor. Proc Natl Acad Sci U S A. 2003; 100(5):2237-2242.
40. Veiga S, Leonelli E, Beelke M, Garcia-Segura LM, Melcangi RC. Neuroactive steroids prevent peripheral myelin alterations induced by diabetes. Neurosci Lett. 2006;402(1-2):150-153.
41. Leonelli E, Bianchi R, Cavaletti G, et al. Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: A multimodal analysis. Neuroscience. 2007;144(4):1293-1304.
42. Sameni HR, Panahi M, Sarkaki A, Saki GH, Makvandi M. The neuroprotective effects of progesterone on experimental diabetic neuropathy in rats. Pak J Biol Sci. 2008;11(16):1994-2000.
43. Melcangi RC, Magnaghi V, Galbiati M, Ghelarducci B, Sebastiani L, Martini L. The action of steroid hormones on peripheral myelin proteins: A possible new tool for the rebuilding of myelin? J Neurocytol. 2000;29(5-6):327-339.
44. Melcangi RC, Azcoitia I, Ballabio M, et al. Neuroactive steroids influence peripheral myelination: A promising opportunity for preventing or treating age-dependent dysfunctions of peripheral nerves. Prog Neurobiol. 2003;71(1):57-66.
45. Azcoitia I, Leonelli E, Magnaghi V, Veiga S, Garcia-Segura LM, Melcangi RC. Progesterone and its derivatives dihydroprogesterone and tetrahydroprogesterone reduce myelin f iber morphological abnormalities and myelin fiber loss in the sciatic nerve of aged rats. Neurobiol Aging. 2003;24(6):853-860.
46. Chavez-Delgado ME, Gomez-Pinedo U, Feria-Velasco A, et al. Ultrastructural analysis of guided nerve regeneration using progesteroneand pregnenolone-loaded chitosan prostheses. J Biomed Mater Res. 2005;74(1):589-600.
47. Melcangi RC, Leonelli E, Magnaghi V, Gherardi G, Nobbio L, Schenone A. Mifepristone (RU 38486) influences expression of glycoprotein Po and morphological parameters at the level of rat sciatic nerve: In vivo observations. Exp Neurol. 2003;184(2):930-938.
48. Meyer L, Venard C, Schaeffer V, Patte-Mensah C, Mensah-Nyagan AG. The biological activity of 3alpha-hydroxysteroid oxido-reductase in the spinal cord regulates thermal and mechanical pain thresholds after sciatic nerve injury. Neurobiol Dis. 2008;30(1):30-41.
49. Meyer L, Patte-Mensah C, Taleb O, Mensah-Nyagan AG. Cellular and functional evidence for a protective action of neurosteroids against vincristine chemotherapy-induced painful neuropathy. Cell Mol Life Sci. 2010;67(17):3017-3034.
50. Aouad M, Charlet A, Rodeau J-L, Poisbeau P. Reduction and prevention of vincristine-induced neuropathic pain symptoms by the non-benzodiazepine anxiolytic etifoxine are mediated by 3α-reduced neurosteroids. Pain. 2009;147(1-3):54-59.
51. Coronel MF, Labombarda F, Villar MJ, De Nicola AF, González SL. Progesterone prevents allodynia after experimental spinal cord injury. J Pain. 2011;12(1):71-83.
52. LaCroix-Fralish ML, Tawfik VL, DeLeo JA. The organizational and activational effects of sex hormones on tactile and thermal hypersensitivity following lumbar nerve root injury in male and female rats. Pain. 2005;114(1-2):71-80.
53. Lacroix-Fralish M, Tawfik V, Nutilemcmenemy N, Deleo J. Progesterone mediates gonadal hormone differences in tactile and thermal hypersensitivity following L5 nerve root ligation in female rats. Neuroscience. 2006;138(2):601-608.
54. Kondo D, Saegusa H, Yabe R, et al. Peripheral-type benzodiazepine receptor antagonist is effective in relieving neuropathic pain in mice. J Pharmacol Sci. 2009;110(1):55-63.
55. Belelli D, Lambert JJ. Neurosteroids: Endogenous regulators of the GABAA receptor. Nat Rev Neurosci. 2005;6(7):565-575.
56. Kondo D, Yabe R, Kurihara T, Saegusa H, Zong S, Tanabe T. Progesterone receptor antagonist is effective in relieving neuropathic pain. Eur J Pharmacol. 2006;541(1-2):44-48.
57. Gambhir M, Mediratta PK, Sharma KK. Evaluation of the analgesic effect of neurosteroids and their possible mechanism of action. Ind J Physiol Pharmacol. 2002;46(2):202-208.
58. Frye CA, Duncan JE. Progesterone metabolites, effective at the GABAA receptor complex, attenuate pain sensitivity in rats. Brain Res. 1994;643(1-2):194-203.
59. Kuba T, Wu HB, Nazarian A, et al. Estradiol and progesterone differentially regulate formalin-induced nociception in ovariectomized female rats. Horm Behav. 2006;49(4):441-449.
60. Ocvirk R, Pearson Murphy BE, Franklin KB, Abbott FV. Antinociceptive profile of ring A-reduced progesterone metabolites in the formalin test. Pain. 2008;138(2):402-409.
61. Charlet A, Lasbennes F, Darbon P, Poisbeau P. Fast non-genomic effects of progesterone-derived neurosteroids on nociceptive thresholds and pain symptoms. Pain. 2008;139(3):603-609.
62. Leonelli E, Ballabio M, Consoli A, Roglio I, Magnaghi V, Melcangi RC. Neuroactive steroids: A therapeutic approach to maintain peripheral nerve integrity during neurodegenerative events. J Mol Neurosci. 2006;28(1):65-76.
63. Melcangi RC, Garcia-Segura LM. Therapeutic approaches to peripheral neuropathy based on neuroactive steroids. Expert Rev Neurother. 2006;6(8):1121-1125.
64. Lambert JJ, Cooper MA, Simmons RD, Weir CJ, Belelli D. Neurosteroids: Endogenous allosteric modulators of GABA(A) receptors. Psychoneuroendocrinology. 2009;34 Suppl 1:S48-S58.